

Authors' Reply

We thank Tabibzadeh *et al.* for their comments. We agree that bisphosphonates are safe and the fear of adynamic bone disease should not be a reason to preclude its use in kidney transplant recipients. We believe that this is one of the main findings of our study.¹ Our data confirmed that we should not have safety concerns with these drugs.

Moreover, besides not having safety issues, bisphosphonates should be used in kidney transplant patients, as suggested by our data. Findings of bone mineral gain on central skeleton assessed by dual-energy X-ray absorptiometry that have been shown by Segaud *et al.*,² our group, and others, must be confronted with the bone loss at peripheral sites. Therefore, we agree that pretransplant bone evaluation should include either high-resolution peripheral quantitative computed tomography or forearm dual-energy X-ray absorptiometry.

As stated in the article and emphasized by Tabibzadeh *et al.*, the design of our study precluded the inclusion of deceased-donor kidney transplant. However, in Brazil and worldwide, this is the most common type of kidney transplant.³ Usually, these patients are older, with longer dialysis duration, a more severe form of CKD-mineral and bone disorder, and lower baseline bone mineral density than the patients included in our study. Indeed, a recent study in our center found that almost half of the patients on dialysis had low bone mineral density.⁴ Therefore, the benefits of zoledronic acid would be more prominent in these patients. We believe that the next step would be performing prospective and placebo-controlled studies, evaluating the effects of prophylactic use of bisphosphonates on fracture prevention. This would help us to identify the subset of patients that would benefit from this therapy and perhaps include

bisphosphonates in the standard care of some kidney transplant recipients.

DISCLOSURES

None.

REFERENCES

1. Marques IDB, Araújo MJCLN, Gracioli FG, Dos Reis LM, Pereira RMR, Alvarenga JC, et al.: A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. *J Am Soc Nephrol* 30: 355–365, 2019
2. Segaud N, Legroux I, Hazzan M, Noel C, Cortet B: Changes in Bone Mineral Density after kidney transplantation: 2-year assessment of a French cohort. *Osteoporos Int* 29: 1165–1175, 2018
3. Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Robinson A, et al.: OPTN/SRTR 2016 annual data report: Kidney. *Am J Transplant* 18 [Suppl 1]: 18–113, 2018
4. Bezerra de Carvalho KS, Vasco RFV, Custodio MR, Jorgetti V, Moysés RMA, Elias RM: Chronic kidney disease is associated with low BMD at the hip but not at the spine [published online ahead of print January 28, 2019]. *Osteoporos Int* 10.1007/s00198-019-04864-4

See related Letter to the Editor, "Biphosphonate Therapy, Risk of Fracture, and Sites of Bone Mineral Density Assessments in Kidney Transplantation," on page 905.

Igor Denizarde Bacelar Marques¹, Rosilene Motta Elias², Rosa Maria Affonso Moysés², and Elias David-Neto^{1,2}

¹Urology Division, Renal Transplant Service and ²Nephrology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

J Am Soc Nephrol 30: 906, 2019.
doi: <https://doi.org/10.1681/ASN.2019020124>

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Igor Denizarde Bacelar Marques, Urology Division, Renal Transplant Service, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Av. Rio Poti 1277, Ap. 1301 Teresina, Piaui 64049-550, Brazil. Email: igordenizarde@yahoo.com.br

Copyright © 2019 by the American Society of Nephrology